CorMedix (CRMD) Projected to Post Quarterly Earnings on Thursday

CorMedix (NASDAQ:CRMD) is expected to announce its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect CorMedix to post earnings of $0.86 per share and revenue of $127.0190 million for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 5, 2026 at 8:30 AM ET.

CorMedix Stock Performance

CRMD traded down $0.31 during trading hours on Tuesday, hitting $6.90. The stock had a trading volume of 1,211,109 shares, compared to its average volume of 2,853,502. The stock has a market cap of $543.65 million, a PE ratio of 3.35 and a beta of 1.31. The company has a quick ratio of 1.73, a current ratio of 1.94 and a debt-to-equity ratio of 0.39. The company’s fifty day simple moving average is $8.49 and its 200 day simple moving average is $10.49. CorMedix has a 1 year low of $5.60 and a 1 year high of $17.43.

CorMedix declared that its board has approved a share repurchase plan on Monday, February 2nd that permits the company to repurchase $75.00 million in shares. This repurchase authorization permits the company to purchase up to 12.3% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Insider Transactions at CorMedix

In related news, Director Alan W. Dunton sold 20,000 shares of the firm’s stock in a transaction on Tuesday, December 30th. The stock was sold at an average price of $13.00, for a total value of $260,000.00. Following the transaction, the director directly owned 40,250 shares of the company’s stock, valued at approximately $523,250. This trade represents a 33.20% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Steven W. Lefkowitz sold 40,000 shares of CorMedix stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $11.88, for a total transaction of $475,200.00. Following the transaction, the director directly owned 80,498 shares in the company, valued at $956,316.24. This represents a 33.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 90,000 shares of company stock worth $1,095,200 in the last quarter. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On CorMedix

Large investors have recently made changes to their positions in the company. State of Tennessee Department of Treasury purchased a new stake in shares of CorMedix during the fourth quarter valued at $223,000. Empowered Funds LLC purchased a new position in CorMedix in the fourth quarter valued at about $1,534,000. VARCOV Co. bought a new position in shares of CorMedix during the 4th quarter worth approximately $1,987,000. Inspire Investing LLC purchased a new stake in shares of CorMedix during the 4th quarter valued at $1,247,000. Finally, Schonfeld Strategic Advisors LLC boosted its position in shares of CorMedix by 105.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 43,431 shares of the company’s stock worth $505,000 after purchasing an additional 22,283 shares in the last quarter. 34.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

CRMD has been the topic of a number of research analyst reports. Truist Financial set a $16.00 target price on CorMedix in a research note on Thursday, January 8th. Needham & Company LLC lowered their price objective on shares of CorMedix from $16.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, January 8th. Weiss Ratings restated a “hold (c)” rating on shares of CorMedix in a report on Wednesday, January 21st. HC Wainwright decreased their price objective on shares of CorMedix from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Finally, Zacks Research lowered CorMedix from a “hold” rating to a “strong sell” rating in a research note on Tuesday, February 10th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $15.86.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.